Mission Bio announced on Dec. 13, 2018 that it has received $30 million in Series B funding from investors that include Agilent Technologies, Cota, and LAM Capital, to develop its Tapestri platform, which was first introduced in 2017. The company, a spinoff of the University of California (San FOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.